The U.S. Food and Drug Administration has approved a new indication for Cytalux (pafolacianine) to assist surgeons in identifying lung cancer lesions in adult patients with known or suspected lung cancer.
More than eight million tons of plastic end up in the oceans every year—a serious danger for the environment and health. Biodegradable bioplastics could provide an alternative. In the journal Angewandte Chemie, a research team has now introduced a new method for the production of protein-based plastics that are easily processable, biodegradable, and biocompatible, as well as having favorable mechanical properties.
A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency’s decision to approve Biogen Inc’s (BIIB.O) Alzheimer’s disease treatment despite the committee’s recommendation against doing so.
Researchers have flipped traditional 3D printing to create some of the most intricate biomedical structures yet, advancing the development of new technologies for regrowing bones and tissue.
Flagship Pioneering unveiled Laronde, a platform company developing Endless RNA™ (eRNA), a novel, engineered form of RNA that can be programmed to express therapeutic proteins inside the body. Flagship initially committed $50 million to support the development of Laronde’s platform and initial pipeline of new medicines.
Fresh off global validation of their Covid-19 vaccine’s extraordinary effectiveness, Russian developers are in talks with China’s CanSino Biologics Inc. to test a combined regimen of their shots to better protect against new virus strains, according to people with knowledge of the matter.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.